The sensitivity of cytology is limited by sampling error, in which the abnormal cells do not get placed on the smear, and reading error, where a few abnormal cells are not identified among the multitude of normal cells that are also present in a well-taken cervical smear. Sensitivities for cytology of only 40-80% for highgrade cervical intraepithelial neoplasia (CIN II/III) have been reported (Reid et al, 1991; Cox et al, 1995; Cuzick et al, 1995) . Furthermore, cytologic screening is poor at detecting glandular lesions or adenocarcinoma, which account for a growing number of cervical cancers (Kjaer and Brinton, 1993; Vizcaino, et al, 1998) . Cytology also has problems with specificity, and the screening programme is overburdened by borderline and mildly dyskaryotic smears, which are costly to follow-up, cause anxiety to the women concerned, but have low predictive value for highgrade pathology (Shafi, 1994; Raffle et al, 1995) .
The causal association between infection with certain HPV types and the development of cervical cancer is now beyond reasonable dispute. The epidemiological data supporting this assertion include reports that HPV DNA can be recovered from over 95% of all cervical tumours (Bosch et al, 1995; Walboomers et al, 1999; Cuzick et al, 2000) , and that women infected with oncogenic HPV types have relative risks of 40-180 for the development of high-grade cervical disease (IARC, 1995; Olsen et al, 1995) . Additionally, molecular studies have identified mechanisms by which high-risk HPV types contribute to carcinogenesis. The World Health Organization and the International Agency for Research on Cancer have officially designated HPVs 16 and 18 as carcinogenic agents. Even higher relative risks (100-500) are reported for persistent HPV infection, which appears to be the key step in cervical carcinogenesis (Nobbenhuis et al, 1999) .
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A plateau of what can be achieved by conventional cytology is now being reached, and the fundamental importance of HPV in the aetiology of cervical cancer has been clearly demonstrated. There is therefore much interest in the use of HPV testing to improve both the effectiveness and cost-effectiveness of cervical screening. Thus, it is timely to consider the role of human papilloma virus (HPV) testing within the cervical screening programme and to review research into its potential implementation.
METHODS
Eight databases were searched, producing a total of about 2100 papers. Additional references were sought by scanning the citations of review articles and books devoted to HPV. Ongoing and unpublished studies were identified, but their results are not included.
The main objectives of the review were as follows. An attempt was made to answer a series of questions formulated at the outset. Papers were divided into broad categories and initially screened by title and abstract using predefined criteria. Complete copies of papers not rejected were obtained, and data were abstracted. Abstractions were done by one author and checked by another. Tabular, graphical and textual methods were used to synthesize the data.
In addition, results from important subsequent publications have also been noted.
RESULTS

Testing methodology
A range of approaches have been used to detect HPV in smear material with widely differing results. The most thoroughly studied methods are now being superseded by newer methods that offer better sensitivity, specificity and reproducibility and are easier to perform. However, many of the most relevant studies are just beginning to reach the literature, and most of the large studies related to screening are still ongoing with at most only preliminary reports available. Currently, two consensus primer PCR systemsthe MY09/11 and the GP5+/6+ pairs -and the second-generation Hybrid Capture system (HC-II) with high risk probes would seem to be the methods of choice (Manos et al, 1989; de Roda Husman et al, 1995; Peyton et al, 1998) . These three methods all have high absolute sensitivity for detecting oncogenic viruses and have the potential for automation. Developments in the form of secondstage assays may help improve specificity without substantially reducing sensitivity.
Natural history
HPV is a sexually transmitted disease with peak prevalence in the age group 20-24 years which gradually declines up to about age 40-45 years, but then may begin to increase slowly again (Herrero et al, 2000) . Most infections are transient, with a median duration of at most 12 months, and pose no risk of cervical neoplasia: only the 10-20% that remain persistent are of concern (Ho et al, 1995; Remmink et al, 1995; Nobbenhuis et al, 1999) . Evidence of infection, either by serology in stored blood samples or by viral DNA in fixed archival specimens, is found many years before serious disease is present, and indicates that infection precedes disease (Walboomers et al, 1995; Lehtinen et al, 1996; Dillner et al, 1997) . Detection of HPV DNA in the absence of cytological abnormalities can also indicate presence of high-grade cervical intraepithelial neoplasia (CIN) which was missed by cytology . Women with minor cytological abnormalities who test negative for oncogenic HPV have a low risk of developing highgrade CIN within 3 years. Little is known about the progressive potential of CIN detected by HPV testing, but missed by cytology or vice versa.
Prevalence
The review was limited to studies using consensus PCR or Hybrid Capture, as other tests are much less reliable and give results that are not comparable. With modern tests, over 95% of all cancers are HPV positive (Bosch et al, 1995; Walboomers et al, 1999; Cuzick et al, 2000) and 75-95% of high-grade CIN lesions are associated with a positive HPV test on exfoliated cells (de Roda Husman et al, 1995; Herrington et al, 1995; Burger et al, 1996; Clavel et al, 1999; Cuzick et al, 1999 ). These and other comparative studies have shown that HPV testing has a greater sensitivity for CIN II/III than cytology. However, greater variability in the HPV positivity rate in 'normal' populations is seen, leading to concern about specificity especially in younger women. This variability reflects a number of factors, including age, extent of sexual exposure, previous disease, and type of assay used. Overall the positivity rate of tests for high-risk HPV types in women not known to have CIN was 13% ranging from 10% for PCR using GP5/6 primers (de Roda Husman et al, 1995; Kruger-Kjaer et al, 1998) to 20% using Hybrid Capture II (Clavel et al, 1999; Cuzick et al, 1999; Hill et al, 1999) . Rates are about half these levels in women aged over 35 years. The rates for HPV type 16 (the most common oncogenic type) are much lower but, if only this type was used the sensitivity for high-grade CIN would be substantially reduced. However, judicious selection of a few HPV types might improve specificity without substantially affecting sensitivity.
Modelling
A number of possibilities exist for introducing HPV testing at different ages and at different screening intervals. It could be used as the sole primary screening modality, as an adjunct to cytology, or in the triage of borderline and mild dyskaryosis. Published modelling studies are limited by the estimates of effectiveness, which are only now becoming available, and the cost of the test, which is still not known for high-volume applications. New modelling studies are presented based on the MISCAN microsimulation programme (Habbema et al, 1984) , using costs based on the British programme, and disease models based on the natural history of HPV-related cervical cancer. In the time available, only baseline calculations could be performed. These were sufficient to show that current knowledge is inadequate for assessing costeffectiveness. The results of the modelling work show that for plausible values of prevalence, screening sensitivities and progression, HPV testing may be effective and cost-effective. For plausible assumptions about the model parameters, there are uses of HPV testing that would provide benefits at a lower cost than many existing healthcare programmes. However, the wide range of results that come from using high and low estimates for these parameters show that more data are needed to refine modelling using more accurate estimates of key parameters.
Economic and social issues
A range of economic issues related to introducing HPV screening were surveyed as well as the very sparse literature on psychosocial aspects. In neither case is the database adequate to draw firm conclusions.
CONCLUSIONS, IMPLICATIONS AND RECOMMENDATIONS
Ten conclusions were made in the report and each of these led to one or more recommendations, the latter being given in italics below.
1. The clearest role for HPV testing at the moment is in the management of women with borderline or mildly dyskaryotic smears (Kjellberg et al, 1998; Manos et al, 1999; Nobbenhuis et al, 1999; Solomon et al, submitted 3. HPV testing appears to be less specific than cytology (as used for referral in the UK screening programme) with false-positive rates ranging from 3-10% in 'normal' women aged over 35 years: false-positive rates are higher in younger women. It should be noted that, if borderline smears are considered positive, the specificity of cytology is also poor particularly in younger women.
Further work is needed to clarify the management of HPVpositive but cytology-negative women and/or to establish methods for determining persistence of HPV infection.
4. The potential exists for HPV testing using one of the newer assays to become the sole method of primary screening, especially for older women, but this will require consistent evidence of high sensitivity for high-grade lesions that are likely to progress to cancer. For younger women, cytology may only need to be performed in HPV-positive women. The cost-effectiveness of such an approach will depend largely on the relative cost of cytology and HPV testing and the screening interval employed.
More studies are needed. 5. A full evaluation of HPV testing should provide information on the length of protection of a negative result and ideally demonstrate a reduction in cancer incidence. Several trials of current HPV tests in the 10 000 patient range are ongoing and should resolve issues of sensitivity, specificity and reproducibility and shed some light on the long-term risk of highgrade CIN following a negative HPV test. 6. A role may exist for HPV testing in post-treatment surveillance of high-grade CIN and localized cancer to determine more quickly and accurately if treatment has completely eradicated local disease. It may be possible to return women to routine surveillance if they become HPV-negative one year after treatment.
Focused trials in the area are needed. 7. Modelling studies show that HPV testing may be a cost-effective screening modality either alone or in conjunction with cytology. These models are dependent on the input parameters, which are currently ill determined due to lack of data. 9. HPV testing with Hybrid Capture appears to be a readily automatable procedure that can achieve high throughput with a low level of technical support. PCR methods using the MY09/11 or GP5+/6+ consensus primers provide good results, but are not yet commercially available.
More work is needed to evaluate the implementation of these assays in different laboratories.
10.HPV testing needs to be viewed in the context of potential improvements in cytology using thin-layer preparations taken from liquid samples and automated reading.
A large study should evaluate the best way of integrating these technologies and the most cost-effective strategy.
